Double-blind randomized proof-of-concept trial of canakinumab in patients with COVID-19 associated cardiac injury and heightened inflammation

AIMS: In coronavirus disease 2019 (COVID-19), myocardial injury is associated with systemic inflammation and higher mortality. Our aim was to perform a proof of concept trial with canakinumab, a monoclonal antibody to interleukin-1β, in patients with COVID-19, myocardial injury, and heightened infla...

Descripción completa

Detalles Bibliográficos
Autores principales: Cremer, Paul C, Sheng, Calvin C, Sahoo, Debasis, Dugar, Siddharth, Prada, Robier Aguillon, Wang, Tom Kai Ming, Hassan, Ossama K Abou, Hernandez-Montfort, Jamie, Wolinsky, David A, Culver, Daniel A, Rajendram, Prabalini, Duggal, Abhijit, Brennan, Danielle M, Wolski, Katherine E, Lincoff, A Michael, Nissen, Steven E, Menon, Venu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9242054/
https://www.ncbi.nlm.nih.gov/pubmed/35923169
http://dx.doi.org/10.1093/ehjopen/oeab002

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9242054/
https://www.ncbi.nlm.nih.gov/pubmed/35923169
http://dx.doi.org/10.1093/ehjopen/oeab002

Ejemplares similares